Clinical trial · Observational
Analysis of Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Nanostructured Sensors
Study of the Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Sensors in Order to Identify Specific Biomarkers. Pre-clinic Evaluation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to identify a pattern of chemoresistive sensors able to recognise the presence of a tumoral pathology from a health state through the analysis of Volatile Organic Compounds inside the specimen. The chemoresistive nanostructured sensors are into an innovative patented device SCENT B1 which can analyse different specimens: blood samples, tissue biopsies, cell cultures. In this study SCENT B1 wil be used to compare the measures of: * tumoral and health tissues taken from different neoplasms after their surgical resection * blood samples from healthy and tumor affected people * pre and post- operative blood samples of tumor affected people
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor, Solid | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood analysis with SCENT B1 | Diagnostic Test | — | UNRESOLVED |
| tissue analysis with SCENT B1 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Tumor affected
- description
- Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
- interventionNames
- Diagnostic Test: blood analysis with SCENT B1
- Diagnostic Test: tissue analysis with SCENT B1
- label
- Control
- description
- Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
- interventionNames
- Diagnostic Test: blood analysis with SCENT B1
Primary outcomes (1)
- measure
- capability of SCENT B1 to distinguish healthy and tumoral specimens
- timeFrame
- up to 3 days after surgery for each patient
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients who undergo to open or laparoscopic surgery for colorectal cancer in election regimen * patients who underwent to open or laparoscopic surgery for colorectal cancer and who have finished chemotherapy or radiotherapy yet Exclusion Criteria: * patients operated in emergency regimen * pregnant women
References
Publications (0)
Data not yet available